Cargando…

Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study

INTRODUCTION: To identify facilitators and barriers towards vaccination in general and specifically against pneumococci, influenza and SARS-CoV-2 in patients with rheumatic musculoskeletal diseases (RMD). METHODS: Between February and April 2021, consecutive patients with RMD were asked to complete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andreica, Ioana, Roman, Iulia, Redeker, Imke, Baraliakos, Xenofon, Braun, Juergen, Kiltz, Uta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Infections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277552/ https://www.ncbi.nlm.nih.gov/pubmed/37295840 http://dx.doi.org/10.1136/rmdopen-2022-002875

Ejemplares similares

SARS-CoV-2 vaccination willingness and predictors in patients with chronic inflammatory rheumatic diseases (CIRD) and without CIRD
por: Roman, Iulia, et al.
Publicado: (2022)

Facilitators and barriers of vaccine uptake in patients with autoimune inflammatory rheumatic disease: a scoping review
por: Neusser, Silke, et al.
Publicado: (2022)

Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study
por: Kiltz, Uta, et al.
Publicado: (2021)

Treatment with adalimumab in patients with chronic inflammatory rheumatic diseases: a study of treatment trajectories on a patient level in routine care
por: Redeker, Imke, et al.
Publicado: (2023)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
por: Andreica, Ioana, et al.
Publicado: (2022)

Management of Axial Spondyloarthritis – Insights into Upadacitinib
por: Braun, Jürgen, et al.
Publicado: (2022)

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence
por: Braun, Jürgen, et al.
Publicado: (2021)

Chronic but not inflammatory changes at the Achilles’ tendon differentiate patients with peripheral spondyloarthritis from other diagnoses – Results from a prospective clinical trial
por: Baraliakos, Xenofon, et al.
Publicado: (2017)

Wie viele Patienten mit entzündlich rheumatischen Erkrankungen haben die technischen Voraussetzungen für Videosprechstunden und sind bereit, fachärztliche Visiten so durchzuführen?
por: Baraliakos, X., et al.
Publicado: (2021)

Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases
por: Hasseli, Rebecca, et al.
Publicado: (2021)

Do patients with ankylosing spondylitis adapt to their disease? Evidence from a ‘then-test’ in patients treated with TNF inhibitors
por: Essers, Ivette, et al.
Publicado: (2015)

Maternal and infant outcomes in pregnancies of women with axial spondyloarthritis compared with matched controls: results from nationwide health insurance data
por: Redeker, Imke, et al.
Publicado: (2022)

Wie gut sind Patienten mit entzündlich rheumatischen Erkrankungen gegen Masern geschützt?
por: Kiltz, U., et al.
Publicado: (2020)

SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry
por: Lawson-Tovey, Saskia, et al.
Publicado: (2022)

Dysfunctional high-density lipoprotein in chronic inflammatory rheumatic diseases
por: Waldecker-Gall, Sabina, et al.
Publicado: (2023)

Current Practice of Imaging-Guided Interventional Procedures in Rheumatic and Musculoskeletal Diseases: Results of a Multinational Multidisciplinary Survey
por: Carubbi, Francesco, et al.
Publicado: (2021)

Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1)
por: Garrido-Cumbrera, Marco, et al.
Publicado: (2021)

Value of imaging to guide interventional procedures in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider
por: Bosch, Philipp, et al.
Publicado: (2021)

Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study
por: Boekel, Laura, et al.
Publicado: (2022)

Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis – the TryCort study
por: Kiltz, Uta, et al.
Publicado: (2017)

Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines
por: Schulze-Koops, Hendrik, et al.
Publicado: (2021)

„Verankerung“ von Klassifikationskriterien für axiale Spondyloarthritis – wie weit ist gut für die Diagnosestellung?
por: Braun, J., et al.
Publicado: (2020)

High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis
por: Krekeler, Martin, et al.
Publicado: (2022)

Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases
por: Sieiro Santos, Cristiana, et al.
Publicado: (2022)

Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)?
por: Laster, Andrew J, et al.
Publicado: (2022)

Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases
por: Hasseli, Rebecca, et al.
Publicado: (2023)

Anxiety and concerns related to the work situation during the second wave of the COVID-19 pandemic in >5000 patients with inflammatory rheumatic disease followed in the DANBIO registry
por: Glintborg, Bente, et al.
Publicado: (2021)

Exercise, infection and rheumatic diseases: what do we know?
por: Calabrese, Leonard, et al.
Publicado: (2021)

Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
por: Santos, Cristiana Sieiro, et al.
Publicado: (2021)

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
por: Baraliakos, Xenofon, et al.
Publicado: (2008)

Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study
por: Álvaro Gracia, Jose María, et al.
Publicado: (2021)

Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases
por: Fragoulis, George E, et al.
Publicado: (2022)

Leitfaden „Geschlechtergerechte Sprache in der DGRh e. V.“
por: Haase, Isabell, et al.
Publicado: (2022)

Neurology of musculoskeletal and rheumatic disorders /
por: Nakano, Kenneth K.
Publicado: (1979)

Maternal and neonatal antibody levels on pertussis vaccination in pregnant women on immune-modulating therapy for rheumatic disease
por: Ghalandari, Nafise, et al.
Publicado: (2023)

Attitude towards and perception of individual safety after SARS-CoV-2 vaccination among German cancer patients
por: Overheu, Oliver, et al.
Publicado: (2022)

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

Biological treatment usage in patients with HIV and rheumatic disease, 2003–2021: long-term safety and follow-up
por: Naovarat, Benjamin Sornrung, et al.
Publicado: (2022)

Drohende Corona-Endemie in einer rheumatologischen Spezialklinik – relative Entwarnung durch konsequente Testung
por: Andreica, I., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_43m97dmi1e988vb3f1d3km7obe